Recursion amends Tempus master agreement, grants RNA model license for $12M

RECURSION PHARMACEUTICALS, INC.

Amendment extends Master Agreement term to six years, eliminates termination-for-convenience clause.
Annual License Fees for years 3-5 revised to $14M each, with at least $4M cash, rest in stock/cash.
Recursion grants Tempus non-exclusive oncology-only license to TxFM RNA model for 2 years.
Tempus pays $12M total license fee in two $6M installments; first on execution, second at one-year.
Tempus provides Recursion access to de-identified pathology records with linked clinical data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.